The Correlation of Mouse Double Minute 4 (MDM4) Polymorphisms (rs4245739, rs1563828, rs11801299, rs10900598, and rs1380576) with Cancer Susceptibility: A Meta-Analysis.
Journal
Medical science monitor : international medical journal of experimental and clinical research
ISSN: 1643-3750
Titre abrégé: Med Sci Monit
Pays: United States
ID NLM: 9609063
Informations de publication
Date de publication:
29 Mar 2022
29 Mar 2022
Historique:
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
8
4
2022
Statut:
epublish
Résumé
BACKGROUND Mouse double minute 4 (MDM4) has been extensively investigated as a negative regulator of P53, its negative feedback loop, and the effect of its genetic polymorphisms on cancers. However, many studies showed varying and even conflicting results. Therefore, we employed meta-analysis to further assess the intensity of the connection between MDM4 polymorphisms and malignancies. MATERIAL AND METHODS We searched eligible articles in 5 databases (Cochrane Library, PubMed, Web of Science, Wan Fang Database, and China National Knowledge Infrastructure) up to August 2021. Odds ratios (ORs) and 95% confidence intervals (CIs) were utilized to probe the correlation of 5 MDM4 polymorphisms (rs4245739, rs1563828, rs11801299, rs10900598, and rs1380576) with carcinomas. We employed meta-regression and subgroup analysis to probe for sources of heterogeneity; Funnel plots, Begg's test, and Egger's test were used to evaluate publication bias. Sensitivity analysis was applied to assess the stability of the study. RESULTS Twenty-two studies, comprising 77 reports with 29 853 cases and 72 045 controls, were included in our meta-analysis. We found that rs4245739 polymorphism was a factor in reducing overall cancer susceptibility (dominant model, OR=0.85, 95% CI=0.76-0.95; heterozygous model, OR=0.86, 95% CI=0.78-0.96; additive model, OR=0.87, 95% CI=0.79-0.95), especially in Asian populations, and it also reduces the risk for esophageal squamous cell carcinoma (ESCC). The remaining 4 SNPs were not associated with cancers. CONCLUSIONS The rs4245739 polymorphism might reduce the risk of malignancies, especially in Asian populations, and it is a risk-reducing factor for ESCC incidence. However, rs1563828, rs11801299, rs10900598, and rs1380576 are not relevant to cancer susceptibility.
Identifiants
pubmed: 35347102
pii: 935671
doi: 10.12659/MSM.935671
pmc: PMC8976448
doi:
Substances chimiques
Cell Cycle Proteins
0
MDM4 protein, human
0
Nuclear Proteins
0
Proto-Oncogene Proteins
0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
e935671Références
Clin Lab. 2016 Jul 01;62(7):1303-1308
pubmed: 28164646
EMBO J. 1996 Oct 1;15(19):5349-57
pubmed: 8895579
PLoS One. 2013 May 28;8(5):e64331
pubmed: 23724042
PLoS One. 2014 Sep 09;9(9):e107047
pubmed: 25203442
Pathol Oncol Res. 2020 Oct;26(4):2409-2423
pubmed: 32556890
Med Sci Monit. 2019 Feb 18;25:1307-1313
pubmed: 30774116
Clin Cancer Res. 2016 Feb 15;22(4):868-76
pubmed: 26459177
Nat Genet. 2013 Apr;45(4):392-8, 398e1-2
pubmed: 23535733
Chem Soc Rev. 2020 Oct 5;49(19):6995-7014
pubmed: 32869798
Pharmacogenet Genomics. 2011 Jul;21(7):388-96
pubmed: 21540763
Int J Biol Markers. 2021 Jun;36(2):17246008211033874
pubmed: 34347554
Lancet Oncol. 2012 Nov;13(11):1133-40
pubmed: 23084521
Genes Cancer. 2011 Apr;2(4):466-74
pubmed: 21779514
Front Oncol. 2020 Aug 05;10:1389
pubmed: 32850448
Cancer Epidemiol. 2019 Feb;58:153-159
pubmed: 30597480
J Med Chem. 2021 Aug 12;64(15):10621-10640
pubmed: 34286973
J Epidemiol Glob Health. 2019 Dec;9(4):217-222
pubmed: 31854162
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Nat Rev Cancer. 2009 Nov;9(11):821-9
pubmed: 19776747
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Breast Cancer Res Treat. 2013 Jul;140(1):151-7
pubmed: 23793604
Int J Biol Markers. 2017 Mar 2;32(1):e62-e67
pubmed: 27646776
Tumour Biol. 2016 Aug;37(8):10697-702
pubmed: 26867771
Onco Targets Ther. 2019 Apr 16;12:2903-2910
pubmed: 31289443
Clin Breast Cancer. 2018 Oct;18(5):e883-e891
pubmed: 29439926
Pharmgenomics Pers Med. 2020 Nov 26;13:673-678
pubmed: 33273845
Zhonghua Wai Ke Za Zhi. 2012 Jan 1;50(1):53-6
pubmed: 22490292
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643228
Oncotarget. 2016 Nov 1;7(44):71718-71726
pubmed: 27687591
PLoS One. 2015 Aug 14;10(8):e0135647
pubmed: 26274820
Melanoma Res. 2014 Jun;24(3):190-7
pubmed: 24625390
Cancer Med. 2015 Dec;4(12):1901-7
pubmed: 26471763
Oncol Lett. 2012 May;3(5):1115-1118
pubmed: 22783402
Nat Rev Cancer. 2013 Feb;13(2):83-96
pubmed: 23303139
J Clin Med. 2020 Jun 01;9(6):
pubmed: 32492903
Oncotarget. 2016 Nov 8;7(45):73935-73944
pubmed: 27738340
Med Oncol. 2015 Jan;32(1):401
pubmed: 25479941
Cancer. 2012 Mar 15;118(6):1684-92
pubmed: 21823114
Oncotarget. 2017 Mar 21;8(12):19547-19555
pubmed: 28099948
Oncotarget. 2016 Aug 23;7(34):55611-55623
pubmed: 27742919
Cancer Cell. 2014 Mar 17;25(3):304-17
pubmed: 24651012
Asian Pac J Cancer Prev. ;18(4):1133-1138
pubmed: 28547953
Med Sci Monit. 2015 Jan 16;21:213-8
pubmed: 25600314